Abstract:The aim of this study was to explore the clinical characteristics of and treatment strategies for interstitial pneumonia induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC). The detailed clinical data of one patient with NSCLC and gefitinib‐induced interstitial pneumonia were compiled and a review of relevant previous studies was performed. Based on this case report and the review, the clinical characteristics, mechanisms and treatment strategies of this rare disease were analyzed. The analyses showed that older, male patients with a long smoking history, high smoking index and adenocarcinoma (particularly bronchoalveolar carcinoma) were more likely to suffer from interstitial pneumonia while taking gefitinib. The onset time of interstitial pneumonia was 1-2 months subsequent to gefitinib administration. The clinical manifestations included chest tightness, shortness of breath, progressive dyspnea, severe hypoxemia and respiratory failure. Diffuse infiltration and alveolar interstitial shadows were observed on the chest tomography scan. In such circumstances, a timely judgment is required, in addition to the withdrawal of gefitinib treatment and the administration of high-dose glucocorticoids, as well as oxygen inhalation and anti-infective therapies, in order to relieve the symptoms. In conclusion, following the onset of gefitinib‐induced interstitial pneumonia, the discontinuation of gefitinib is likely to alleviate the suffering of the majority of patients. Early interstitial pneumonia is not an absolute index for the permanent discontinuation of gefitinib treatment. It is necessary to comprehensively consider the benefits and hazards of gefitinib for the patients. Introduction Gefitinib, an epidermal growth factor receptor (EGFR) type 1 tyrosine kinase inhibitor, blocks the signal transduction pathway implicated in the proliferation and survival of cancer cells (1). The use of gefitinib to treat patients with advanced non-small-cell-lung cancer (NSCLC) has raised significant concern among physicians. Gefitinib is better-tolerated and less toxic than conventional cytotoxic drugs; however, gefitinib-induced interstitial lung disease (ILD) has been demonstrated to be a serious adverse effect (2). Phase II studies showed that the objective response rates achieved after gefitinib treatment were between 10 and 20%, with minimal toxicities; mainly an acne-like rash and mild diarrhea, in patients with recurrent non-small cell lung cancer (the IDEAL trials) (3). In subsequent phase III trials, the addition of gefitinib to standard platinum-based chemotherapy failed to demonstrate a survival advantage in patients with untreated non-small cell lung cancer (the INTACT trials) (4,5). The worldwide incidence of ILD was approximately 1% (2% in the Japanese post-marketing experience and approximately 0.3% in a United States expanded access program). The median time to onset of ILD was 24 days in the Japan group and 42 days in the United States group. Approximately one‐third of all ILD cases caused by gefitinib have been fatal (6). In this study, a case of gefitinib‐induced interstitial pneumonia is described and previous case reports between 2003 and 2011 are reviewed, with the aims of summarizing the clinical features, mechanisms and treatment strategies of gefitinib‐induced interstitial pneumonia and providing a reference for medication safety in the clinical treatment of NSCLC.

Clinical analysis on erlotinib-induced acute interstitial lung disease in patients with NSCLC

Four cases of interstitial lung disease induced by erlotinib and a review of the literatures]

Meta-analysis of Occurrence of Interstitial Lung Disease in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Efficacy and Safety of Erlotinib in the Treatment for Advanced Non-Small Cell Lung Cancer in Chinese Patients

Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer

Risk of Interstitial Lung Disease Associated with EGFR-TKIs in Advanced Non-Small-cell Lung Cancer: a Meta-Analysis of 24 Phase III Clinical Trials

Clinical Analysis of 76 Cases of Erlotinib-Induced Skin Rash in the Treatment of Non-Small Cell Lung Cancer

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

Clinical Efficacy of Erlotinib in Patients Previously Treated for Advanced Non‐small Cell Lung Cancer

Clinical analysis of 12 cases of lung cancer associated with interstitial lung diseases

Clinical analysis of 21 patients with interstitial lung disease complicated with lung cancer

Evaluation of erlotinib as a salvage treatment for non-small-cell lung cancer(NSCLC)patients after gefitinib failure

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy

Efficacy and Safety of Erlotinib on Advanced Non-small Cell Lung Cancer

[Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer: A Report of 92 Eases.].

Radiation Pneumonitis in Patients with Non–Small-Cell Lung Cancer Treated with Erlotinib Concurrent with Thoracic Radiotherapy

Preliminary study of immunology mechanism of erlotinib-induced skin rash

Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study

Phase Ⅱ Trial of Gefitinib in Female Patients with Previously Treated Advanced Non-Small Cell Lung Cancer